文献速递垂体与肾上腺疾病

CYP11B1/CYP11B2双重免疫组化与KCNJ5突变检测在原发性醛固酮增多症中的应用

Double CYP11B1/CYP11B2 Immunohistochemistry and Detection of KCNJ5 Mutations in Primary Aldosteronism.
PubMed 文献 · J Clin Endocrinol Metab · 2024-01-01

研究对127例手术治愈的原发性醛固酮增多症患者的肾上腺醛固酮瘤进行CYP11B1/CYP11B2双重免疫组化、Sanger测序和NGS。双重免疫组化揭示3种模式,KCNJ5突变率在各模式间差异显著:模式1为17.8%,模式2为71.4%,模式3为10.7%(χ2=22.492,P<.001)。NGS在Sanger阴性病例中检出10%的KCNJ5突变,并在61%的病例中检出额外突变。

要点

  • 双重免疫组化可区分3种CYP11B2/CYP11B1表达模式。
  • KCNJ5突变率在模式1、2、3分别为17.8%、71.4%、10.7%(P<.001)。
  • NGS在Sanger阴性者中检出10%的KCNJ5突变,并在61%病例中检出额外突变。

核心结论

  • NGS在許多Sanger測序陰性的腎上腺中檢出了突變。
  • KCNJ5突變在免疫組化模式間的不同分佈表明,聚焦CYP11B2陽性區域的免疫組化引導測序方案可能無法代表整個切除腎上腺的突變狀態。

研究设计与样本

  • 研究納入127例連續的、同意手術並治癒的原發性醛固酮增多症患者的腎上腺醛固酮瘤。
  • 採用CYP11B1和CYP11B2雙重免疫組化、Sanger測序和NGS進行檢測。

主要发现

  • 雙重免疫組化揭示3種模式:模式1為CYP11B2陽性腺瘤,模式2為CYP11B1/CYP11B2混合陽性腺瘤,模式3為多個小CYP11B2陽性結節。
  • Sanger測序在44%的腎上腺中檢出KCNJ5突變。
  • NGS在Sanger陰性病例中檢出10%的KCNJ5突變,並在61%的病例中檢出額外突變。
  • KCNJ5突變率在模式1為17.8%,模式2為71.4%,模式3為10.7%(χ2=22.492,P<.001)。

局限性

  • 原文未報告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The search for somatic mutations in adrenals resected from patients with primary aldosteronism (PA) is performed by Sanger sequencing, often implemented with immunohistochemistry (IHC)-guidance focused on aldosterone-producing (CYP11B2-positive) areas. OBJECTIVE: To investigate the impact of double IHC for CYP11B1 and CYP11B2 on Sanger and next-generation sequencing (NGS). METHODS: We investigated 127 consecutive adrenal aldosterone-producing adenomas from consenting surgically cured PA patients using double IHC for CYP11B1 and CYP11B2, by Sanger sequencing and NGS. RESULTS: Double IHC for CYP11B2 and CYP11B1 revealed 3 distinct patterns: CYP11B2-positive adenoma (pattern 1), mixed CYP11B1/CYP11B2-positive adenoma (pattern 2), and adrenals with multiple small CYP11B2-positive nodules (pattern 3). Sanger sequencing allowed detection of KCNJ5 mutations in 44% of the adrenals; NGS revealed such mutations in 10% of those negative at Sanger and additional mutations in 61% of the cases. Importantly the rate of KCNJ5 mutations differed across patterns: 17.8% in pattern 1, 71.4% in pattern 2, and 10.7% in pattern 3 (χ2 = 22.492, P < .001). CONCLUSION: NGS allowed detection of mutations in many adrenals that tested negative at Sanger sequencing. Moreover, the different distribution of KCNJ5 mutations across IHC patterns indicates that IHC-guided sequencing protocols selecting CYP11B2-positive areas could furnish results that might not be representative of the entire mutational status of the excised adrenal, which is important at a time when KCNJ5 mutations are suggested to drive management of patients with aldosterone-producing adenomas.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Caroccia B, Lenzini L, Ceolotto G, et al. Double CYP11B1/CYP11B2 Immunohistochemistry and Detection of KCNJ5 Mutations in Primary Aldosteronism. J Clin Endocrinol Metab. 2024. PMID: 38888173. doi:10.1210/clinem/dgae411

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。